Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 30, 2024

SELL
$14.75 - $17.26 $170,333 - $199,318
-11,548 Closed
0 $0
Q1 2019

Aug 30, 2024

SELL
$13.94 - $17.58 $47,814 - $60,299
-3,430 Reduced 22.9%
11,548 $186 Million
Q4 2018

Aug 30, 2024

BUY
$13.33 - $18.66 $199,656 - $279,489
14,978 New
14,978 $219 Million
Q3 2018

Aug 30, 2024

SELL
$16.68 - $18.41 $14,344 - $15,832
-860 Reduced 5.43%
14,978 $272 Million
Q2 2018

Aug 30, 2024

BUY
$16.87 - $20.3 $60,613 - $72,937
3,593 Added 29.34%
15,838 $267 Million
Q1 2018

Aug 30, 2024

BUY
$17.06 - $21.2 $208,899 - $259,594
12,245 New
12,245 $240 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.35B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.